Yi Larson - 20 Jan 2023 Form 4 Insider Report for LianBio (LIANY)

Role
Chief Financial Officer
Signature
By: /s/ Angela Chen, Attorney-in-Fact
Issuer symbol
LIANY
Transactions as of
20 Jan 2023
Net transactions value
$0
Form type
4
Filing time
24 Jan 2023, 15:12:23 UTC
Previous filing
27 Jun 2022
Next filing
31 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIAN Stock Option (Right to Buy) Award $0 +464,099 $0.000000 464,099 20 Jan 2023 Ordinary Shares 464,099 $2.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option will vest and become exercisable on January 20, 2024; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 20, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.